{"entity":{"id":"duo-e","kind":"trial","name":"DUO-E / GOG-3041 / ENGOT-EN10","aka":[],"tldr":"A third immunotherapy confirmed the benefit in dMMR disease and hinted that adding olaparib helps the mismatch-repair-proficient majority.","summary":"Durvalumab alone: PFS HR 0.71 overall and 0.42 in dMMR. Durvalumab + olaparib: PFS HR 0.55 overall and 0.57 in pMMR (JCO 2023). FDA approved durvalumab with chemotherapy for dMMR disease in June 2024; the EU approved both the durvalumab and durvalumab + olaparib regimens (pMMR for the latter) in 2024.","status":"positive","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT04269200","url":"https://clinicaltrials.gov/study/NCT04269200"},{"label":"JCO 2023","url":"https://ascopubs.org/doi/10.1200/JCO.23.02132"}],"tags":[],"related":[],"cancers":["endometrial","endometrial-mmr-deficient","advanced-recurrent-endometrial-cancer"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pdl1","parp"],"drugs":["durvalumab","olaparib","carboplatin","paclitaxel"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":["msi"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04269200","phase":"3","setting":"Newly diagnosed advanced or recurrent endometrial cancer: chemotherapy + durvalumab, then durvalumab ± olaparib maintenance, vs chemotherapy","sponsor":"AstraZeneca","result":"PFS HR 0.42 (dMMR, durvalumab); 0.57 (pMMR, durvalumab + olaparib).","started":"2020-05-05","startedType":"actual","yearReported":2023,"enrolled":718,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression-free survival (dMMR, durvalumab)","unit":"HR","arms":[{"name":"Durvalumab + chemo"},{"name":"Chemo"}],"hr":0.42,"ci":[0.22,0.8],"source":"https://ascopubs.org/doi/10.1200/JCO.23.02132"},{"endpoint":"Progression-free survival (pMMR, durvalumab + olaparib)","unit":"HR","arms":[{"name":"Durvalumab + olaparib + chemo"},{"name":"Chemo"}],"hr":0.57,"ci":[0.44,0.73],"source":"https://ascopubs.org/doi/10.1200/JCO.23.02132"}]},"route":"/trials/duo-e/","neighbours":{"cancer":[{"id":"advanced-recurrent-endometrial-cancer","kind":"cancer","name":"Advanced or recurrent endometrial cancer","route":"/cancers/advanced-recurrent-endometrial-cancer/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"endometrial-mmr-deficient","kind":"cancer","name":"Mismatch-repair-deficient endometrial cancer","route":"/cancers/endometrial-mmr-deficient/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"term":[{"id":"msi","kind":"term","name":"Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR)","route":"/terms/msi/"}],"pairing":[{"id":"chemo-io-first-line-endometrial","kind":"pairing","name":"Chemotherapy + PD-1/PD-L1 blockade, first-line advanced endometrial cancer","route":"/pairings/chemo-io-first-line-endometrial/"}],"paper":[{"id":"paper-duo-e-jco-2023","kind":"paper","name":"DUO-E: durvalumab with carboplatin-paclitaxel and maintenance durvalumab with or without olaparib in advanced endometrial cancer","route":"/key-papers/paper-duo-e-jco-2023/"}]}}